Leukemia

Blinatumomab has been granted full approval by the FDA for patients with B-cell acute lymphoblastic leukemia and minimal residual disease of 0.01% or more.

Investigators pause their evaluation of SC-DARIC33 in pediatric relapsed/refractory acute myeloid leukemia following a grade 5 serious adverse effect in the phase 1 PLAT-08 trial.

Investigators identify only 1 death related to treatment with acalabrutinib among older, frail patients with chronic lymphocytic leukemia in the phase 2 CLL-FRAIL trial.

Adding blinatumomab to Interfant-06 chemotherapy appears to be feasible and safe in the treatment infants with acute lymphoblastic leukemia in a phase 2 trial.

Zanubrutinib and acalabrutinib produce similar safety profiles in the treatment of patients with relapsed/refractory chronic lymphocytic leukemia in the phase 3 ASCEND and APLINE trials.

Venetoclax plus obinutuzumab with or without ibrutinib demonstrates superiority over standard chemoimmunotherapy in fit patients with chronic lymphocytic leukemia.

Treatment with lisocabtagene maraleucel correlates with a reduction in CD19-positive cells in responders and patients with stable disease among those with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma in the phase 1/2 TRANSCEND CLL 004 trial.

A real-world population of patients with relapsed/refractory B-cell acute lymphoblastic leukemia are reported to have had a high rate of complete remissions following treatment with brexucabtagene autoleucel.

Obecatagene autoleucel also appears to result in a high rate of minimal residual disease negativity in a population of patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Zanubrutinib appears to produce significantly better progression-free survival and overall cardiac safety compared with ibrutinib in the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.

Sustained improvements in leukemia outcomes in low- and middle-income countries are feasible with cross border programs, according to an expert from the University of California, San Diego.

Voruciclib plus venetoclax appears to yield no dose-limiting toxicities in a small population of patients with acute myeloid leukemia, according to early findings from a phase 1 study.

Rates of relapse and worse survival were associated with persistent FLT3-ITD or NPM1 variants prior to allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia.

Asciminib does not appear to interfere with the general life activities of patients with resistant/intolerant chronic phase chronic myeloid leukemia in the phase 3 ASCEMBL trial.

China’s National Medical Products Administration has also approved zanubrutinib as a treatment for patients with Waldenström macroglobulinemia based on findings from the phase 3 ASPEN trial.

The novel radiotherapy Iomab-B prolongs survival and improves clinical outcomes among patients with relapsed/refractory acute myeloid leukemia, according to data from the phase 3 SIERRA trial.

The FDA extends the Prescription Drug User Fee Act date to July 24, 2023 for quizartinib in the management of newly diagnosed FLT3-ITD mutation–positive acute myeloid leukemia.

Despite an improvement in disease-free survival, patients 60 years or over with acute myeloid leukemia do not appear to have a survival benefit from allo-HCT during first complete remission compared with consolidation chemotherapy.

Jun J. Yang, PhD, reviews the use of ex vivo drug sensitivity profiles and in vivo early treatment response for patients with acute lymphoblastic leukemia.

Investigators highlight the importance of building partnerships between CAR T-cell centers and external hospitals to increase treatment referrals and access to clinical trials for patients with B-cell acute lymphoblastic leukemia.

Experts discuss findings presented at ASH 2022 regarding chronic lymphocytic leukemia, and how they can be applied to clinical practice.

A panel of experts from Moffitt and Mayo discuss newly published data from the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition.

A detailed discussion on first-line treatment options for chronic GVHD and options for patients with steroid-refractory chronic GVHD.

Experts on graft-vs-host disease discuss patient monitoring and education, and a patient details his experience with GVHD.

A panel of GVHD experts give a comprehensive overview of the presentations of acute and chronic graft-vs-host disease.